First Postpartum Depression Drug Fast Tracked and Licensed by FDA
On Aug. 4, 2023, the U.S. Food and Drug Administration (FDA) fast tracked licensure of the oral prescription medication Zurzuvae (zuranolone), manufactured by Sage Therapeutics, Inc. as a treatment for postpartum depression. Postpartum affects roughly one in seven women and typically begins after childbirth but, for some women, it can begin during later stages of […]
Many U.S. Universities End COVID-19 Vaccine Mandates
Many universities and colleges in the United States required proof of COVID-19 vaccinations for attendance when the shots were first introduced and, until recently, many of these academic institutions also required receipt of the new COVID bivalent booster shots.1 But almost two years since the rollout of the original COVID shots, many universities and colleges […]
